All News
Novel Proteomic Biomarker Set in Osteoarthritis
NIH funded researchers from Duke University have developed a set of serum proteomic biomarkers that successfully predict clinically relevant knee osteoarthritis (KOA) progression (both structural change and joint pain) over a 2 year period.
Read ArticlePhysician Burnout Remains, Less So in Rheumatology
The 2023 Medscape Survey on Physician burnout ranks rheumatology at #10; which is down from #2 when the survey was last done in 2021.
Read ArticleACR Urges CMS to Reconsider Copay Assistant Programs in CMS Proposed Rule
The Health and Human Services Notice of Benefit and Payment Parameters proposed rule for 2024 does not revise policies related to copay assistance and patient deductibles.
Read ArticleHope for Biologic Treatment of Hidradenitis Suppurativa
A meta-analysis of trials using biologics [adalimumab (ADA), ustekinumab (UST) and secukinumab (SEC)] in the the management of hidradenitis suppurativa (HS) suggests promising results, but more controlled, rigorous studies are needed.
Read ArticleHerpes Zoster with JAK Inhibitors
JAK inhibitors are approved for several immune-mediated inflammatory diseases and carry a higher than usual risk of herpes zoster in certain conditions like rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and ulcerative colitis.
Read ArticleWomen at high risk of fracture remain untreated for osteoporosis
An estimated 100,000 to 120,000 fragility fractures occur annually in the Netherlands, the equivalent of at least 11 broken bones per hour.
Read ArticleRheumatic Disease - IBD Overlap
Nearly one in 10 patients with inflammatory bowel disease (IBD) also have rheumatologic disorders, meaning that specialists have to talk to each other to develop a treatment plan that works for both conditions, a researcher suggested.
Read ArticleAI Passes U.S. Medical Licensing Exam
Two artificial intelligence (AI) programs -- including ChatGPT -- have passed the U.S. Medical Licensing Examination (USMLE), according to two recent papers.
Read ArticleVEXAS may be more common than expected
A great study of a recently described rheumatologic/hematologic disorder VEXAS (vacuoles, E1-ubiquitin-activating enzyme, X-linked, autoinflammatory, somatic) syndrome recently appeared in JAMA, describing the frequency and presentations of UBA1 variant.
Read ArticleBlood Test Identifies Osteoarthritis Progression
A new blood test that can identify progression of osteoarthritis in the knee is more accurate than current methods, providing an important tool to advance research and speed discovery of new therapies.
Read ArticleVariable Pregnancy Outcomes with Belimumab in SLE
An analysis of the belimumab clinical trials, the Belimumab Pregnancy Registry (BPR), and postmarketing/spontaneous reports looked at outcomes in pregnant systemic lupus erythematosus (SLE) exposed to belimumab reported there are few pregnancies and confounding disease and comorbidity factors to
Read ArticlePeriprosthetic Joint Infections
Recent NEJM has reviewed arthroplasty-associated infection and periprosthetic joint infections (PJI), noting this is a rare event; notably these infections are caused by skin microorganisms introduced during arthroplasty surgery or may be seeded post-surgically, via hematogenously spread or compromised local tissues (skin or bone).
Read ArticleJAK-pot Study: To Cycle or Switch after JAK inhibitor Failure?
Data from 17 international registries (JAK-pot collaboration) suggest that for Rheumatoid arthritis (RA) patients failing their first janus kinase inhibitor (JAKi), it did not matter if they were cycled to another JAKi or switched to a biologic disease-modifying antirheumatic drug (bDMARD).
Read ArticleBurden of BMI on Costs of Musculoskeletal Diseases
A cross-sectional global study shows a substantial impact of obesity and BMI on the health and economic impact of patients with musculoskeletal (MSK) disorders.
Read ArticlePsA Til Death Do Us Part (1.20.2023)
Dr. Jack Cush reviews the highlights from the past week on RheumNow.com.
Read ArticleAS, but not PsA, has Increased Mortality Risk
Inflammatory disorders are often accompanied by an increased mortality risk, either from secondary malignancy, infection or cardiovascular disease.
Read ArticlePhase III Trials Back Bimekizumab for Spondyloarthritis
Bimekizumab, an investigational biologic drug targeting interleukin (IL)-17A/F, appeared highly effective in patients with axial spondyloarthritis (axSpA), researchers said.
Read ArticlePoorer health outcomes for at-risk patients with fractures
People at high risk of fracture who also have complex or multiple chronic medical conditions are less likely to receive treatment for the underlying osteoporosis and also have poorer health outcomes, according to a new study from the Garvan Institute of Medical Research.
Read ArticleElevated Uric Acid Is Associated With New‐Onset Atrial Fibrillation
A Longitudinal Swedish study has shown that elevated serum uric acid (SUA) levels has cardiovascular implications and may predict the development of atrial fibrillation (AFib).
Read ArticleRA Disease Activity and Alcohol Use
Despite its well known toxicities, alcohol is known to be antiinflammatory. The effects of alcohol use in rheumatoid arthritis (RA) is less known, but a recent study suggests that alcohol consumption was dose-dependently associated with lower disease activity and higher health-related quality of life in RA patients.
Read Article


